Sökning: "Recurrent venous thromboembolism"
Visar resultat 1 - 5 av 7 avhandlingar innehållade orden Recurrent venous thromboembolism.
1. Identification of genetic biomarkers for the risk prediction of recurrent venous thromboembolism. Risk prediction of recurrent VTE
Sammanfattning : Background: Venous thromboembolism (VTE) is the third most frequent life-threatening cardiovascular disease with an annual incidence rate of 1-2 per 1000 person-years. After the diagnosis for primary VTE, about 20-30% patients develop a recurrence within 5-years. LÄS MER
2. Treatment of deep vein thrombosis and risk of recurrent venous thromboembolism
Sammanfattning : A cute deep vein thrombosis (DVT) and pulmonary embolism (PE) are different clinical presentations of the same underlying disease, namely venous thromboembolism (VTE), which is a common and potentially fatal condition. Risk factors associated with the first and probably also subsequent events of VTE are hereditary or acquired. LÄS MER
3. Long-term consequences of venous thromboembolism in women
Sammanfattning : Background: Venous thromboembolism (VTE) is the third most common cardiovascular disease with a high recurrence rate. There is a risk of chronic complications affecting health- related quality-of life (QoL). LÄS MER
4. Venous thromboembolism in women : risk factors and long term follow-up
Sammanfattning : Background: Venous thromboembolism (VTE) is a common and potentially life threatening disease. Women have different risk factors than men at both first and recurrent VTE. The aim of this thesis was to further identify and explore risk factors for VTE in young and middle aged women. LÄS MER
5. Exploration of novel mechanisms and biomarkers for venous thromboembolism : a genetics and proteomics study
Sammanfattning : Background: Venous thromboembolism (VTE) contributes to a large health burden and incidence increases exponentially with age. ~25% patients will experience a recurrent event and there is a 2-fold risk for death in the following years. Risk prediction remains a challenge. LÄS MER